

## AUTHOR INDEX

Volume 41

January to June 1990

- Aedo, A-R, 569  
 Allonen, H., 353, 485  
 Alvarez-Sanchez, F., 169  
 Anand, S., 323  
 Ansari, S., 323  
 Ashwell, E., 363  
 Ball, M.J., 363  
 Banerjee, A., 293, 301  
 Baulieu, E.E., 85  
 Blain, R., 605  
 Blankenstein, M.A., 345  
 Bleau, G., 605  
 Borggaard, B., 259  
 Brache, V., 169  
 Butchart, A., 583  
 Bygdeman, M., 283, 461  
 Caflisch, C.R., 207  
 Chakravarti, R.N., 179, 419  
 Chaudhary, J., 641  
 Chavinie, J., 221  
 Cheng, J., 389  
 Chi, I-C, 495  
 Chiang, S.T., 39  
 Chillik, C.F., 85  
 Chitcharoentum, M., 431  
 Chompootawee, S., 507  
 Cilenti, D., 9  
 Cochon, L., 169  
 Dada, O., 569  
 Danforth, D.R., 623  
 Das, R.P., 641  
 Datta, J.K., 93  
 Davidhazy, A., 591  
 Demarest, K., 399  
 De Plunkett, T.L., 221  
 Dhall, K., 293, 301  
 Dickmann, Z., 189  
 Diczfalusy, E., 569  
 Dominik, R., 495  
 Dubois, C., 85  
 DuBose, Jr., T.D., 207  
 Dusitsin, N., 507  
 Elger, W.A.G., 197  
 El-Tawil, A., 317  
 Epelboin, S., 221  
 Fahmy, K., 317  
 Fang, Q.L., 663  
 Farooq, A., 323  
 Farr, G., 495  
 Faundes, A., 169  
 Fotherby, K., 533, 557  
 Fraser, H.M., 73  
 Fugere, P., 1  
 Gao, J., 485  
 Gates, D.S., 9  
 Gaur, A., 301  
 Gillmer, M.D.G., 363  
 Goldstuck, N.D., 583  
 Gottlieb, C., 461  
 Gréen, K., 283, 461  
 Gross, W., 245  
 Grubb, G.S., 27  
 Guha, S.K., 323  
 Gupta, I., 179, 419  
 Hahn, D., 623  
 Hahn, D.W., 399  
 Haspels, A.A., 345  
 He, C-h, 557  
 Heidt, F., 245  
 Helm, P., 475  
 Hingorani, V., 293, 301  
 Ho, P.C., 55  
 Hodgen, G.D., 85, 623  
 Hofmeyer, G.J., 583  
 Hsiu, J.G., 623  
 Hu, W-w, 389  
 Ibrahim, M., 317  
 Ismail, H., 317  
 Jackson, M., 363  
 Jayawardena, K.G.I., 213  
 Jia, M., 353  
 Jivasak-Apimas, S., 9  
 Johannisson, E., 569  
 Juneja, R., 179, 419  
 Jung-Hoffmann, C., 245  
 Kharat, I., 293  
 Kjaer, A., 259  
 Klavon, S.L., 27  
 Kloosterboer, H.J., 345  
 Koetsawang, S., 9  
 Krishna, U., 293, 301  
 Kuhl, H., 245  
 Kumar, G.P., 633  
 Kumar, M., 519  
 Kumar, S., 293, 301  
 Kune, G.A., 19  
 Kune, S., 19  
 Kwan, M.S.W., 55  
 Laloraya, M., 633  
 Laloraya, M.M., 633  
 Landgren, B-M, 569  
 Lebech, A-M, 259  
 Leckym, N-A, 9  
 Lewin, F., 221

# CONTRACEPTION

- Li, G.Y., 663
- Li, L.S., 663
- Li, M.F., 663
- Liao, D-l, 557
- Lidegaard, Ø., 475
- Lin, Y.C., 431
- Lindstedt, G., 271
- Liu, Q.L., 617
- Liu, W.T., 55
- Lobo, R.A., 39
- Lohiya, N.K., 519
- Luo, H-z, 389
- Luukkainen, T, 353, 485
- Ma, Q.L., 663
- Majumdar, N., 93
- Majumdar, S., 179, 419
- Majumdar, S.S., 641
- Martin, A., 411
- März, W., 245
- Matlin, S.A., 557
- Mauvis-Jarvis, P., 221
- McGuire, J.L., 399, 623
- Milsom, I., 271
- Mori, A., 655
- Mowszowicz, I., 221
- Nagata, Y., 635
- Nair, N.S., 293
- Patil, R.K., 197
- Phillips, A., 399
- Pongubalan, J.M.R., 197
- Puri, C.P., 197
- Qian, S.Z., 617
- Rådestad, A., 283
- Ratnasooriya, W.D., 213, 441
- Refn, H., 259
- Reidenberg, M.M., 377
- Rikihiya, Y., 431
- Roberts, K.D., 605
- Robinson, N., 495
- Roh, S.I., 623
- Roy, S., 293, 301
- Rybo, G., 271
- Sammour, M., 317
- Sanyal, S.N., 179
- Schierup, L., 259
- Sethi, N., 333
- Shahani, S.M., 293, 301
- Sharma, D.N., 323
- Sharma, K., 519
- Sharma, N.C., 301
- Sharma, R.K., 641
- Sharma, S., 519
- Sheridan, P., 605
- Shi, F.J., 617
- Shi, Y-e, 557
- Sitruk-Ware, R., 221
- Singh, O., 293, 301
- Singh, R.K., 333
- Sonnendecker, E.W.W., 383
- Sonoda, T., 655
- Spitz, I.M., 221
- Srivastava, R.K., 333
- Stanczyk, F.Z., 39
- Stube, R., 591
- Sun, B-l, 485
- Suwanichati, S., 9
- Swahn, M.L., 461
- Swahney, H., 293
- Takeuchi, K., 655
- Talwar, G.P., 293, 301
- Tang, Y.L., 617
- Tejada, A.S., 169
- Terranova, P.F., 189
- Thalabard, J-C, 221
- Thijssen, J.H.H., 345
- Tournaire, M., 221
- Ulmann, A., 85
- Van der Vange, N., 345
- Van Look, P.F.A., 557
- Vézina, D., 605
- Vickery, B.H., 411
- Vince, P.M., 557
- Voeller, B., 591
- Wadsworth, R.M., 213, 441
- Wali, A., 179, 419
- Wallace, E.M., 63
- Waller, D.P., 411
- Wang, J-d, 389
- Wang, S-l, 485
- Wang, Y., 617
- Watson, L.F., 19
- Williams, R.F., 623
- WHO Task Force on Long-Acting  
Systemic Agents for Fertility  
Regulation, 105, 125, 143, 151
- Williams, R.F., 623
- Wolf, J.P., 85
- Wong, F., 399
- Wu, D.F., 377
- Wu, F.C.W., 63
- Wu, J.T., 551
- Wu, S-c, 485
- Wu, X.M., 663
- Xiao, B., 353
- Xu, D.Z., 663
- Xu, J-q, 557
- Xu, R-h, 389
- Yamamoto, S., 655
- Yaneva, H., 221
- Yang, Y.Q., 551
- Zaneveld, L.J.D., 411
- Zhang, H.Y., 663
- Zhang, X., 353
- Zhao, S-c, 453
- Zhong, C.Q., 617
- Zhou, L., 353
- Zhu, P-d, 389
- Zhu, Y-h, 557

## SUBJECT INDEX

## VOLUME 41

January to June 1990

- Abortifacient, use of RU486, 221  
 Acceptability,  
     levonorgestrel-releasing IUD, 485  
     menfegol vaginal tablets, 507  
     nonoxynol-9 vaginal tablets, 507  
     Norplant<sup>R</sup>-2, 485  
 Air Burst Test of condoms, cinematography of rupture, 591  
 Androgen receptor studies, various progestins (rat), 399  
 Androgenic activity, various progestins (rat), 399  
 Anesthetics + cycloheximide, synergism to achieve ovulation  
     blockade (hamster), 189  
 Anodyne-lubricant jelly with dicaine, effect on cervical  
     dilatation, 663  
 Anti-hCG immunization, effect on menstrual cycle, 293  
 Anti-hCG vaccine, clinical trial, 301  
 Anti-protamine antibodies, in vasectomized men, 605  
 Anti-sperm antibodies, in vasectomized men, 605  
 Antiprogestin,  
     RU 486, 85, 221, 283, 461, 551  
     ZK 98.299, 197  
 Arachidonic acid bioconversion, effect of RU 486, 283  
 Biphasic ethinylestradiol + desogestrel, effect on SHBG, CBG  
     and testosterone levels, 345  
 Bleeding pattern,  
     effect of levonorgestrel, 151  
     levonorgestrel-releasing IUD, 353, 485  
     Norplant<sup>R</sup>-2, 485  
     vaginal ring releasing levonorgestrel, 151  
 Body weight, effect of gossypol (rat), 431  
 Breakage of IUDs, fracture force measurements, 583  
 CA<sup>++</sup>-APTase activity in sperm, effect of verapamil (guinea  
     pig), 419  
 CA<sup>++</sup>-uptake by sperm, effect of verapamil (guinea pig), 419  
 Calcium content of sperm, effect of verapamil (guinea  
     pig), 419  
 Cancer of colon and rectum, association with use of oral  
     contraceptives, 19  
 Carbohydrate metabolism, effect of triphasic  
     contraceptives, 363  
 CBG (corticol binding globulin)  
 CBG level, effect of combined oral contraceptives, 345  
 Cervical dilatation,  
     Anodyne-lubricant jelly with dicaine, 663  
     effect of lidocaine, 663  
     effect of RU 486, 283

## CONTRACEPTION

- Cervix,
  - effect of Cu T-200, 317
  - effect of Lippes loop, 317
- $\alpha$ -Chlorohydrin, effect on pH of testis and epididymis (rat), 207
- Clinical effects,
  - use of Multiload IUDs, 271
  - use of triphasic contraceptives, 259
- Clinical evaluation, RU486 used as an abortifacient, 221
- Clinical performance,
  - levonorgestrel-releasing IUD, 485
  - Norplant<sup>R</sup>-2, 485
  - Nova-T, 1
- Clinical trial, anti-hCG vaccines, 301
- Coagulation proteins, effect of triphasic contraceptives, 363
- Cobalt chloride, effect on sperm motility and spermatozoal surfaces, 633
- Colorectal cancer and oral contraceptives use, 19
- Colposcopic findings, effect of IUD use, 317
- Condom, cinematography of burst during Air Burst Test, 591
- Contraceptive efficacy, tamoxifen (hamster), 93
- Contraceptive use, influence on pelvic inflammatory disease, 475
- Contraceptive vaccine,
  - clinical trial, 301
  - effect on menstrual cycle, 293
- Copper 7, study on breakage forces, 583
- Copper T220, effect on endometrium, 389
- Cortisol level, effect of RU486, 221
- Cu T-200, cyto-colpo-pathological study, 317
- Cycloheximide + anesthetics, synergism to achieve ovulation blockade (hamster), 189
- Cytological findings, effect of IUD use, 317
- 17-Deacetylated norgestimate, progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Detirelix,
  - effect on ovulatory cycle (monkey), 73
  - LHRH antagonist, 73
- Dilatation of cervix,
  - Anodyne-lubricant jelly with dicaine, 663
  - effect of lidocaine, 663
  - effect of RU 486, 283
- Discontinuation,
  - use of foaming vaginal tablets, 507
  - use of vaginal ring releasing levonorgestrel, 151
- Discontinuation rate, use of vaginal ring releasing levonorgestrel, 105, 125
- Effectiveness,
  - menfegol vaginal tablets, 507
  - nonoxynol-9 vaginal tablets, 507

- Efficacy,  
     levonorgestrel-releasing IUD, 485  
     Norplant<sup>R</sup>-2, 485  
     use of RU486 as an abortifacient, 221  
     use of vaginal ring releasing levonorgestrel, 105
- Egg transport, effect of RU 486 (mouse), 551
- Electrocoagulation, long-term follow-up following  
     laparoscopic sterilization, 9
- Embryonic development, effect of RU 486 (mouse), 551
- Embryos,  
     effect of IUD-bearing uterine secretions (mouse), 655  
     effect of RU 486 (monkey), 85
- Enalapril, effect on sperm motility, 213
- Endocervical cultures, use of Nova-T, 1
- Endocrine status, effect of anti-hCG vaccines, 301
- Endometrium,  
     effect of GnRH antagonist + norgestimate (monkey), 623  
     effect of levonorgestrel, 569  
     effect of norethisterone, 569  
     morphometry of microvessels with use of IUDs, 389
- Epididymis, effect of  $\alpha$ -chlorohydrin (rat), 207
- Estradiol level,  
     effect of anti-hCG vaccines, 301  
     effect of depot medroxyprogesterone acetate +  
         testosterone oenanthate, 63  
     effect of GnRH antagonist + norgestimate  
         (monkey), 623  
     effect of levonorgestrel, 169, 353, 569  
     effect of LHRH antagonist (monkey), 73  
     effect of norethisterone, 569  
     effect of RU 486, 221  
     effect of tamoxifen (hamster), 93
- Ethinylestradiol, pharmacokinetics, 39
- Ethinylestradiol + cyproterone acetate, effect on SHBG,  
     CBG and testosterone levels, 345
- Ethinylestradiol + desogestrel,  
     effect on serum lipids, 55  
     effect on serum lipids and lipoproteins, 245  
     effect on SHBG, CBG and testosterone levels, 345
- Ethinylestradiol + gestodene,  
     clinical and hormonal effects, 259  
     effect on coagulation proteins, 363  
     effect on metabolism, 363  
     effect on serum lipids and lipoproteins, 245
- Ethinylestradiol + levonorgestrel,  
     clinical and hormonal effects, 259  
     effect on coagulation proteins, 363  
     effect on metabolism, 363  
     effect on serum lipids, 55  
     effect on SHBG, CBG and testosterone levels, 345  
     pharmacokinetics, 39
- Ethinylestradiol + norethisterone, effect on SHBG, CBG  
     and testosterone levels, 345

## CONTRACEPTION

- Ethinylestradiol level, following administration of ethinylestradiol + levonorgestrel, 39
- Ethinylloestradiol + desogestrel, potency and pharmacokinetics, 533
- Ethinylloestradiol + gestodene, potency and pharmacokinetics, 533
- Ethinylloestradiol + levonorgestrel, potency and pharmacokinetics, 533
- Ethinylloestradiol + norethisterone, potency and pharmacokinetics, 533
- Expulsion,
  - Norplant<sup>R</sup> implants, 27
  - use of vaginal ring releasing levonorgestrel, 125
- Expulsion rate, Nova-T, 1
- Ferritin concentration, effect of Multiload IUDs, 271
- Fertility,
  - effect of ketoconazole (rat), 411
  - effect of prazosin (rat), 441
- Foetal outcome, effect of antiprogesterin ZK 98.299 (monkey), 197
- Food intake, effect of gossypol (rat), 431
- Fracture forces, study on breakage of IUDs, 583
- FSH level,
  - effect of GnRH antagonist + norgestimate (monkey) 623
  - effect of levonorgestrel, 569
  - effect of LHRH antagonist (monkey), 73
  - effect of norethisterone, 569
- Gestagens,
  - pharmacokinetics and pharmacodynamic effects, 533
  - potency, 533
  - serum binding, 533
  - serum concentrations, 533
- Gestodene, progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Gestodene level, following administration of ethinyl-estradiol + gestodene, 259
- GnRH (gonadotropin releasing hormone)
- GnRH antagonist + norgestimate,
  - effect on endometrium and ovary (monkey), 623
  - effectiveness as contraceptive (monkey), 623
- Gossypol,
  - effect on sperm and hypokalemia (monkey), 519
  - effect on sperm function, 617
  - effect on thyroid function (rat), 431
  - stereoselective activity (rat), 377
- Gossypol + potassium chloride, effect on sperm and hypokalemia (monkey), 519
- HCG level, effect of RU486, 221
- Hematological parameters,
  - effect of anti-hCG vaccines, 301
  - effect of Multiload IUDs, 271
- Hemolytic effects, gossypol (rat), 377
- Histological findings, effect of IUD use, 317

- Histological studies, effect of RU486 used as an abortifacient, 221
- Hormonal effects, use of triphasic contraceptives, 259
- Hormone levels, effect of gossypol, 617
- Hulka clip, long-term follow-up following laparoscopic sterilization, 9
- Hypokalemia, effect of gossypol with potassium chloride (monkey), 519
- Immunization with anti-hCG vaccine,
  - clinical trial, 301
  - effect on menstrual cycle, 293
- Implant contraceptive, levonorgestrel, 27, 169, 485
- Infection, insertion site of Norplant<sup>R</sup> system, 27
- Insertion site complications, use of Norplant<sup>R</sup> system, 27
- Intrauterine device (IUD),
  - copper 7, 583
  - copper T220, 389
  - Cu T-200, 317
  - levonorgestrel-releasing, 353, 389, 485
  - Lippes Loop, 317
  - MLCu-250, 271, 583
  - MLCu-375, 271, 583
  - Nova-T, 1, 583
  - stainless steel ring, 389
- Iron status, effect of Multiload IUDs, 271
- Isomers of gossypol, study of stereoselective activity (rat), 377
- IUD (intrauterine device)
- IUD insertions, effect of uterine position, 495
- IUD performance, effect of uterine position, 495
- IUD thread, male partner complaint, 341
- IUD-bearing uterine secretions, effect on embryos (mouse), 655
- IUD-related infection, 341
- 3-Keto desogestrel, progestational and androgenic receptor binding affinities (rat, rabbit), 399
- 3-Keto norgestimate, progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Ketoconazole,
  - effect on fertility (rat), 411
  - effect on sperm (rat), 411
- Laparoscopic sterilization, long-term follow-up, 9
- Levonorgestrel,
  - effects on pituitary, ovary and endometrium, 569
  - pharmacokinetics, 39, 557
  - progestational and androgenic receptor binding affinities (rat, rabbit), 399
  - use as postcoital contraceptive, 557

## CONTRACEPTION

- Levonorgestrel intravaginal ring,
  - bleeding patterns, 151
  - contraceptive efficacy, 105
  - discontinuation rate, 105, 125
  - expulsions, 125
  - pregnancy rate, 105, 143
  - relationship between pregnancy rate and body weight, 143
  - removals, 125
  - side effects, 105
- Levonorgestrel level,
  - following administration of ethinylestradiol + levonorgestrel, 39, 259
  - following administration of two formulations of levonorgestrel tablets, 557
  - following use of levonorgestrel-releasing IUD, 353
- Levonorgestrel-releasing IUD,
  - clinical trial, 485
  - effect on endometrium, 389
  - pharmacokinetic and pharmacodynamic studies, 353
- LH level,
  - effect of GnRH antagonist + norgestimate (monkey), 623
  - effect of levonorgestrel, 569
  - effect of LHRH antagonist (monkey), 73
  - effect of norethisterone, 569
- LHRH (luteinizing hormone releasing hormone)
- LHRH antagonist,
  - detirelix, 73
  - effect on ovulatory cycle (monkey), 73
- Lidocaine, effect on cervical dilatation, 663
- Lipid levels, effect of triphasic contraceptives, 363
- Lipid metabolism,
  - effect of depot medroxyprogesterone acetate + testosterone oenanthate, 63
  - effect of ethinylestradiol + desogestrel, 55, 245
  - effect of ethinylestradiol + gestodene, 245
  - effect of ethinyl oestradiol + levonorgestrel, 55
- Lippes loop, cyto-colpo-pathological study, 317
- Local reaction, insertion site of Norplant<sup>R</sup> system, 27
- Male contraceptive,
  - $\alpha$ -chlorohydrin (rat), 207
  - depot-medroxyprogesterone acetate + testosterone oenanthate, 63
- Medroxyprogesterone acetate + testosterone oenanthate,
  - effect on hormone levels, 63
  - effect on serum lipoproteins, 63
- Medroxyprogesterone acetate level, following administration of depot medroxyprogesterone acetate + testosterone oenanthate, 63
- Menfegol vaginal tablets, evaluation of safety, effectiveness and acceptability, 507
- Menstrual blood loss, effect of Multiload IUDs, 271



- Menstrual cycle,  
     effect of anti-hCG vaccines, 293  
     effect of levonorgestrel, 569  
     effect of norethisterone, 569
- Metabolic parameters, effect of anti-hCG vaccines, 301
- Metabolism, effect of triphasic contraceptives, 363
- 9-Methylene PGE<sub>2</sub> + RU 486, use for termination of pregnancy, 461
- MLCu 250/375, study on breakage forces, 583
- Morphometric study of endometrium, use of IUDs, 389
- Multiload IUDs,  
     effect of uterine position on insertions and performance, 495  
     effect on menstrual blood loss and iron status, 271
- Nal-Glu GnRH antagonist + norgestimate, effectiveness as contraceptive (monkey), 623
- Nonoxynol-9 vaginal tablets, evaluation of safety, effectiveness and acceptability, 507
- Norethisterone, effects on pituitary, ovary and endometrium, 569
- Norgestimate,  
     progestational and androgenic activities (rat, rabbit), 399  
     progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Norgestimate + Nal-Glu GnRH antagonist, effectiveness as contraceptive (monkey), 623
- Norplant<sup>R</sup>,  
     effect on ovarian endocrine function, 169  
     insertion site complications during use, 27
- Norplant<sup>R</sup>-2, clinical trial, 485
- Nova-T,  
     clinical performance, 1  
     study on breakage forces, 583
- Occlusion of vas deferens,  
     percutaneous injection of polyurethane elastomer plug, 453  
     use of styrene maleic anhydride (monkey), 323  
     use of styrene maleic anhydride (rat), 333
- Oral contraceptive,  
     biphasic ethinylestradiol + desogestrel, 345  
     ethinylestradiol + cyproterone acetate, 345  
     ethinylestradiol + desogestrel, 55, 245, 345, 533  
     ethinylestradiol + gestodene, 245, 533  
     ethinylestradiol + levonorgestrel, 55, 345, 533  
     ethinylestradiol + norethisterone, 345, 533  
     triphasic ethinylestradiol + gestodene, 259, 345, 363  
     triphasic ethinylestradiol + levonorgestrel, 39, 259, 345, 363
- Oral contraceptive use and colorectal cancer, 19
- Ovarian endocrine function, effect of norgestrel, 169
- Ovary, effect of GnRH antagonist + norgestimate (monkey), 623
- Ovulation blockage, synergism of cycloheximide and anesthetics (hamster), 189

## CONTRACEPTION

- Ovulatory cycle, effect of LHRH antagonist (monkey), 73
- Pelvic inflammatory disease, influence of contraceptive, sexual and social life events, 475
- Penile pain, IUD thread, 341
- Percutaneous injection of polyurethane elastomer plug, vas deferens occlusion, 453
- pH in seminiferous tubules and epididymal duct, effect of  $\alpha$ -chlorohydrin (rat) 207
- Pharmaceutical characteristics, two formulations of levonorgestrel tablets, 557
- Pharmacokinetic and pharmacodynamic studies, levonorgestrel-releasing IUD, 353
- Pharmacokinetic parameters, two formulations of levonorgestrel tablets, 557
- Pharmacokinetics,
  - ethinylestradiol + levonorgestrel, 39
  - gestagens, 533
- Polyurethane elastomer occlusion of vas deferens, recovery of fertility after removal, 453
- Polyurethane elastomer plug, percutaneous injection for vas deferens occlusion, 453
- Postcoital contraceptive, levonorgestrel, 557
- Potassium chloride + gossypol, effect on sperm and hypokalemia (monkey), 519
- Potassium level,
  - effect of gossypol (monkey), 519
  - effect of gossypol + potassium chloride (monkey), 519
- Potency, gestagens, 533
- Prazosin, effect on fertility (rat), 441
- Pregnancy, effect of antiprogesterin ZK 98.299 (monkey), 197
- Pregnancy rate,
  - Nova-T, 1
  - use of vaginal ring releasing levonorgestrel, 105, 143
- Pregnancy rate and weight relationship, use of vaginal ring releasing levonorgestrel, 143
- Progestational activity, various progestins (rabbit), 399
- Progesterone,
  - effect on RU 486-treated embryos (monkey), 85
  - progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Progesterone antagonist,
  - effect on foetal outcome (monkey), 197
  - effect on pregnancy (monkey), 197
  - ZK 98.299, 197
- Progesterone level,
  - effect of anti-hCG vaccines, 301
  - effect of GnRH antagonist + norgestimate (monkey), 623
  - effect of levonorgestrel, 169, 353, 569
  - effect of LHRH antagonist (monkey), 73
  - effect of norethisterone, 569
  - effect of RU486, 221
  - effect of tamoxifen (hamster), 93
  - effect of ZK 98.299 (monkey), 197

- Progestin receptor studies, various progestins (rabbit), 399
- Progestins, progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Progestogens, hormonal and endometrial effects, 569
- Prostaglandin analogue, 9-methylene PGE<sub>2</sub>, 461
- Protamine sulfate administration, effect on vasectomized men, 605
- Removal rate, Nova-T, 1
- Removals, use of vaginal ring releasing levonorgestrel, 125
- Reproductive parameters, effect of prazosin (rat), 441
- RU 486,
  - effect on egg transport (mouse), 551
  - effect on embryo development (mouse), 551
  - effect on embryos (monkey), 85
  - effect on uterine cervix, 283
  - use as abortifacient, 221
- RU 486 + 9-methylene PGE<sub>2</sub>, use for termination of pregnancy, 461
- RU 486 level, following administration of RU486 as an abortifacient, 221
- Rupture of condoms, cinematography of burst during Air Burst Test, 591
- Safety,
  - menfegol vaginal tablets, 507
  - nonoxynol-9 vaginal tablets, 507
- Secretions from IUD-bearing uterus, effect on embryos (mouse), 655
- Seminal plasma, effect of STS-557 (monkey), 641
- Seminology,
  - effect of gossypol (monkey), 519
  - effect of gossypol + potassium chloride (monkey), 519
- Sexual parameters, influence on pelvic inflammatory disease, 475
- SHBG (sex hormone binding globulin)
- SHBG level,
  - effect of combined oral contraceptives, 345
  - effect of depot medroxyprogesterone acetate + testosterone oenanthate, 63
  - effect of ethinylestradiol + gestodene, 259
  - effect of ethinylestradiol + levonorgestrel, 259
  - effect of levonorgestrel, 557
  - effect of triphasic contraceptive, 363
- Side effects,
  - use of levonorgestrel-releasing IUD, 485
  - use of Norplant<sup>R</sup>-2, 485
  - use of RU486 as an abortifacient, 221
  - use of vaginal ring releasing levonorgestrel, 105
- Social parameters, influence on pelvic inflammatory disease, 475
- Sodium level,
  - effect of gossypol (monkey), 519
  - effect of gossypol + potassium chloride (monkey), 519

## CONTRACEPTION

- Sperm count,
  - effect of ketoconazole (rat), 411
  - effect of STS-557 (monkey), 641
  - effect of verapamil (guinea pig), 179
- Sperm function, long after cessation of gossypol treatment, 617
- Sperm motility,
  - effect of cobalt chloride and recovery with cysteine, 633
  - effect of enalapril, 213
  - effect of ketoconazole (rat), 411
  - effect of STS-557 (monkey) 641
  - effect of verapamil (guinea pig), 179
- Spermatozoa,
  - effect of cobalt chloride, 633
  - effect of STS-557 (monkey), 61
  - effect of verapamil (guinea pig), 419
- Spermatozoal functions, effect of verapamil (guinea pig), 179
- Stainless steel ring, effect on endometrium, 389
- Stereoselective activity, gossypol (rat), 377
- Sterilization,
  - Hulka clip, 9
  - tubal ring occlusion, 9
  - unipolar electrocoagulation, 9
- STS-557, effect on spermatozoa (monkey), 641
- STS-557 level, following administration of STS-557 (monkey), 641
- Styrene maleic anhydride,
  - effect of vas deferens (rat), 333
  - use for vas deferens occlusion (monkey), 323
- Synergism of cycloheximide with anesthetics, effect on ovulation (hamster), 189
- T-shaped copper IUDs, effect of uterine position on insertions and performance, 495
- Tamoxifen, contraceptive efficacy (hamster), 93
- Termination of pregnancy, use of RU 486 + 9-methylene PGE<sub>2</sub>, 461
- Testis,
  - effect of  $\alpha$ -chlorohydrin (rat), 207
  - effect of verapamil (guinea pig), 179
- Testosterone level,
  - effect of combined oral contraceptives, 345
  - effect of gossypol (monkey), 519
  - effect of gossypol + potassium chloride (monkey), 519
  - effect of STS-557 (monkey), 641
  - following administration of depot medroxyprogesterone acetate + testosterone oenanthate, 63
- Thyroid function, effect of gossypol (rat), 431
- Transaminase activity,
  - effect of gossypol (monkey), 519
  - effect of gossypol + potassium chloride (monkey), 519

- Triphasic ethinylestradiol + gestodene,
  - clinical and hormonal effects, 259
  - effect on coagulation proteins, 363
  - effect on metabolism, 363
  - effect on SHBG, CBG and testosterone levels, 345
- Triphasic ethinylestradiol + levonorgestrel,
  - clinical and hormonal effects, 259
  - effect on coagulation proteins, 363
  - effect on metabolism, 363
  - effect on SHBG, CBG and testosterone levels, 345
  - pharmacokinetics, 39
- Tubal ring occlusion, long-term follow-up following laparoscopic sterilization, 9
- Uterine contractility, effect of RU 486 + 9-methylene PGE<sub>2</sub>, 461
- Uterine enzymes, effect of tamoxifen (hamster), 93
- Uterine position, effect on insertions and performance of IUDs, 495
- Uterine secretions of IUD-bearing uterus,
  - effect on embryos (mouse), 655
  - leucocyte count (mouse), 655
  - prostaglandin levels (mouse), 655
- Vaginal contraceptive,
  - menfegol tablets, 507
  - nonoxynol-9 tablets, 507
- Vaginal ring, releasing levonorgestrel, 105, 125, 143, 151
- Vas deferens, effect of styrene maleic anhydride (rat), 333
- Vas deferens occlusion,
  - percutaneous injection of polyurethane elastomer plug, 453
  - use of styrene maleic anhydride (monkey), 323
- Vasectomized men, effect of protamine sulfate administration, 605
- Verapamil,
  - effect on spermatozoa (guinea pig), 419
  - effect on spermatozoal functions (guinea pig), 179
- Weight and pregnancy rate relationship, use of vaginal ring releasing levonorgestrel, 143
- ZK 98.299,
  - effect on foetal outcome (monkey), 197
  - effect on pregnancy (monkey), 197